Quick Answer
bioAffinity Technologies, Inc. reported Research And Development Expense of $1.38 million for the year ending 2025.
- bioAffinity Technologies, Inc. showed a decrease of -5.3% in Research And Development Expense from 2024 to 2025.
- This data is from bioAffinity Technologies, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2021: $330.8 thousand | Q1 2022: $279.8 thousand | Q2 2022: $248.4 thousand | Q3 2022: $319.7 thousand | Q1 2023: $369.6 thousand | Q2 2023: $335.1 thousand | Q3 2023: $330.4 thousand | Q1 2024: $393.6 thousand | Q2 2024: $402.4 thousand | Q3 2024: $274.5 thousand | Q1 2025: $367.4 thousand | Q2 2025: $311.4 thousand | Q3 2025: $330.6 thousand.
- Over the full 5 years of available data (2021 to 2025), bioAffinity Technologies, Inc.'s Research And Development Expense has grown by 37.3%.
- Historical annual values: Fiscal year 2025: $1.38 million | Fiscal year 2024: $1.46 million | Fiscal year 2023: $1.47 million | Fiscal year 2022: $1.38 million | Fiscal year 2021: $1.01 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: